Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

NIH 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Dermatologic 2Gastrointestinal 1

Conditions

Skin Neoplasms 2Sarcoma, Kaposi 2HIV Infections 2Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Semaxinib × Dermatologic × Clear all
NCT00002226 2005-06-24

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

NIH AIDS Clinical Trials Information Service

Phase NA Completed
30 enrolled
DermatologicSarcoma

Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

NCT00005931 2005-06-24

SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment

NIH AIDS Clinical Trials Information Service

Phase 2 Completed
30 enrolled
DermatologicSarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡